Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations
July 01, 2024 08:00 ET
|
Ovid Therapeutics Inc.
The Phase 1 study for OV888/GV101 capsule met its objective, demonstrating a favorable safety and tolerability profile with no serious adverse eventsSecondary endpoint results indicate that the target...
Ovid Therapeutics Reports on Takeda’s Announcement of Phase 3 Topline Study Results for Soticlestat
June 17, 2024 06:55 ET
|
Ovid Therapeutics Inc.
Takeda’s Skyline study in Dravet syndrome narrowly missed its primary endpoint of reduction in convulsive seizure frequency and showed clinically meaningful and significant effects in multiple key...
Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results
May 14, 2024 08:00 ET
|
Ovid Therapeutics Inc.
Takeda has completed two Phase 3 trials studying soticlestat as a treatment for Lennox-Gastaut syndrome and Dravet syndrome; topline data are anticipated in Takeda's H1 2024 fiscal yearA Phase 1,...
Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
May 13, 2024 07:00 ET
|
Ovid Therapeutics Inc.
NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives...
Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
April 04, 2024 08:00 ET
|
Ovid Therapeutics Inc.
NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by rare epilepsies...
Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results
March 08, 2024 08:00 ET
|
Ovid Therapeutics Inc.
Two pivotal Phase 3 clinical trials studying soticlestat as a treatment for Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS) completed enrollment; Takeda anticipates topline data readout by or...
Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
February 28, 2024 08:00 ET
|
Ovid Therapeutics Inc.
NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives...
Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 06, 2024 08:00 ET
|
Ovid Therapeutics Inc.
NEW YORK, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives...
Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)
December 01, 2023 07:30 ET
|
Ovid Therapeutics Inc.
Posters with new preclinical data on the pharmacokinetic and pharmacodynamic behavior of OV329 support its profile as a potential best-in-class GABA aminotransferase inhibitor Disease models provide...
Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates
November 03, 2023 08:00 ET
|
Ovid Therapeutics Inc.
Received a $30 million payment from Ligand for the sale of a 13% interest in the potential future royalties and milestone payments owed to Ovid for soticlestat The Company extended its expected cash...